Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse.

Wang, Huanrong; Liu, Lei; Yan, Jiaqin; Ma, Wang; Du, Yabing; Zhang, Tengfei

Wang, Huanrong; Liu, Lei; Yan, Jiaqin; Ma, Wang; Du, Yabing; Zhang, Tengfei.

Afiliação

Wang H; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liu L; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yan J; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ma W; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Du Y; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhang T; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Front Oncol ; 12: 1097816, 2022.

Article em En | MEDLINE | ID: mdl-36741689

Palavras-chave

derived neutrophil-to-lymphocyte ratio; first-line treatment; folate receptor-positive circulating tumor cell; lung cancer; lymphopenia; prognosis; relapse

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google